1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China Traditional Chinese Medicine Holdings Co. Ltd.

China Traditional Chinese Medicine Holdings Co. Ltd.

1.17
HKD
+0.03
(+2.19%)
10.52BMarket Cap
Mar 19Next Earn
China Traditional Chinese Medicine Holdings Co. Ltd.
HKEX:570
(Hong Kong Exchange)

Recent

price

1.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.46
0.46
0.58
0.68
1.05
1.01
1.47
1.88
2.33
2.84
2.94
3.78
2.84
3.6
3.28
2.93
- -
Revenue per Share
0.03
0.03
0.09
0.1
0.16
0.17
0.22
0.26
0.3
0.32
0.33
0.38
0.15
0.26
0.01
-0.07
- -
Basic EPS, GAAP
- -
-0.07
- -
- -
0.09
0.08
0.27
0.14
-0.01
0.08
-0.2
-0.02
0.11
0.14
0.41
0.39
- -
Free Cash Flow per Basic Share
- -
- -
0.06
- -
- -
- -
0.06
0.07
0.1
0.1
0.04
0.05
0.06
0.05
- -
0.08
- -
Dividend per Share
0.4
0.43
0.46
1.09
1.26
2.48
2.61
2.81
3.09
3.3
3.59
3.92
4
4.2
4.21
4.06
4.06
Book Value per Share
0.25
0.29
0.33
0.23
0.41
0.25
0.31
0.51
1.07
1.32
1.62
1.98
2.15
2.43
2.6
2.67
2.67
Tangible Book Value per Share
1,728
1,783
1,783
2,051
2,534
3,687
4,450
4,432
4,822
5,036
5,036
5,036
5,036
5,036
5,036
5,036
5,036
Basic Weighted Avg Shares
800
822
1,032
1,395
2,650
3,709
6,533
8,338
11,259
14,321
14,806
19,053
14,304
18,122
16,510
14,745
- -
Sales/Revenue/Turnover
12.68
9.71
20.79
18.37
20.86
17.56
20.96
20.7
17.8
17.32
16.74
14.2
8.32
7.5
5.6
4.21
- -
Operating Margin (%)
46
46
36
68
119
162
337
423
510
591
684
850
1,099
1,133
1,130
1,159
- -
Depreciation Expense
52
58
169
198
413
626
967
1,170
1,439
1,588
1,663
1,933
764
1,285
54
-342
- -
Net Income, GAAP
25.3
21.96
20.05
16.09
14.39
17.28
16.66
16.32
15.6
17.7
16.57
15.75
14.18
- -
87.27
- -
- -
Effective Tax Rate (%)
6.49
7.09
16.33
14.23
15.59
16.87
14.8
14.04
12.78
11.09
11.23
10.14
5.34
7.09
0.33
-2.32
- -
Profit Margin (%)
88
91
165
514
961
2,393
4,564
6,689
5,853
4,177
7,597
9,439
7,864
10,467
11,039
9,975
9,975
Working Capital
- -
- -
- -
668
671
850
2,909
4,515
2,225
262
2,542
2,893
529
2,191
1,892
260
260
LT Debt
724
782
846
2,835
3,257
12,140
12,756
13,815
17,511
19,051
20,896
22,662
22,948
23,937
23,933
23,028
23,028
Total Equity
9.04
6.8
16.08
8.48
11.01
6.49
7.25
8.29
8.44
8.26
8.08
8.57
3.26
- -
0.15
- -
- -
Return on Invested Capital (%)
3.68
6.6
15.49
8.49
11
6.99
5.81
6.82
7.31
6.81
6.56
7.17
3.58
- -
0.4
- -
- -
Return on Capital (%)
7.89
7.88
21.1
11.06
13.9
8.74
8.51
9.74
10.28
9.87
9.59
10.23
3.83
6.22
0.26
-1.64
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2,124
3,300
2,234
LT Borrowings
1,817
224
208
LT Finance Leases
75
74
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,036
5,036
5,036
Market Capitalization
10,931
10,157
9,457

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
18,840
18,971
17,708
Cash, Cash Equivalents & STI
5,336
5,173
5,050
Accounts Receivable, Net
8,169
8,570
8,379
Inventories
4,783
4,668
3,711
Total Current Liabilities
7,800
9,449
7,734
Payables & Accruals
- -
- -
- -
ST Debt
2,124
3,300
2,234
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.89%
2.05%
-3.78%
Free Cash Flow
-151.89%
-133.78%
-5.53%
Net Income, GAAP
-69.09%
-160.92%
-732.68%
Sales/Revenue/Turnover
18.02%
2.17%
-10.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
18,122
2024
- -
- -
16,510
2025
- -
- -
14,745

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.26
2024
- -
- -
0.01
2025
- -
- -
-0.07

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.05
2024
- -
- -
- -
2025
- -
- -
0.08
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) is an investment holding company engaged in the research, development, production and sale of traditional Chinese medicine (TCM) and pharmaceutical products primarily in the People's Republic of China. The company operates through four main segments: Yi Fang, which manufactures and sells concentrated TCM granules, TCM healthcare products and decoction pieces under the Yi Fang brand; Tian Jiang, which produces concentrated TCM granules, decoction pieces, TCM healthcare products under the Tian Jiang brand and provides Chinese medical healthcare solutions including consultation, diagnosis, physiotherapy and prescriptions through offline institutions; Tong Ji Tang; and Medi-World, which manufactures and sells TCM finished drugs under brands such as Medi-World, De Zhong and Feng Liao Xing. It also engages in the sale of medical herbs, trading of pharmaceutical products, property leasing and provision of TCM marketing, advertising and consulting services, with products sold to hospitals and retail pharmacies. A subsidiary of China National Pharmaceutical Group Co., Ltd. (Sinopharm Group), the company traces its origins to 1955, with headquarters and management center in Foshan, Guangdong, and is listed on the main board of the Hong Kong Stock Exchange. In late 2025, the company renewed key continuing connected transactions with Sinopharm Group entities, including the Financial Services Framework Agreement effective through December 31, 2025, and Master Purchase and Master Supply Agreements extending to 2028, aimed at enhancing financial services, procurement and product sales. For the first half of 2025 ended June 30, it reported revenue of approximately RMB2.99 billion from concentrated TCM granules among other segments, alongside recognition of goodwill impairment in its Tian Jiang unit due to underperformance.